# US 2026/0216311 A1 · Thi-inducing adjuvant comprising combination of different nucleic acid adjuvants and use of same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216311 A1
- Document ID: US20260216311A1
- Status: Published application
- Kind: A1
- Application number: 19/303,754
- Filed: 2025-08-19
- Published: 2026-07-30
- Earliest claimed: 2014-11-20
- Assignees: Ken ISHII
- Inventors: Ken ISHII; Etsushi KURODA; Burcu Temizoz
- Web page: https://patentgrep.com/patent/US20260216311A1

## CPC

- A61K 39/12: Viral antigens
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/7084: Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/525: {Virus}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/575: {humoral response}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.

## Claims

### Claim 1

A combination of a CpG oligonucleotide and a STING agonist.

### Claim at position 2

-28. (canceled)

### Claim 29 (depends on 1)

The combination of claim 1, formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier or excipient.

### Claim 30 (depends on 1)

The combination of claim 1, packaged as a kit comprising a first container comprising the CpG oligonucleotide and a second container comprising the STING agonist.

### Claim 31 (depends on 29)

The pharmaceutical composition of claim 29, wherein the CpG oligonucleotide is a type K/B CpG oligonucleotide comprising at least one non-methylated CpG dinucleotide motif, and the STING agonist is a cyclic dinucleotide (CDN).

### Claim 32 (depends on 1)

The combination of claim 1, wherein the CpG oligonucleotide is a type K/B CpG oligonucleotide.

### Claim 33 (depends on 32)

The combination of claim 32, wherein the CpG oligonucleotide is selected from the group consisting of K3 CpG (SEQ ID NO: 1), CpG 1826 (SEQ ID NO: 2), and D35 CpG (SEQ ID NO: 3).

### Claim 34 (depends on 1)

The combination of claim 1, wherein the STING agonist is selected from the group consisting of cGAMP, 3′3′-cGAMP, c-di-GMP, c-di-AMP, 2′3′-cGAMP, and DMXAA.

### Claim 35 (depends on 1)

The combination of claim 1, wherein the CpG oligonucleotide reduces or eliminates IgE-inducing action of the STING agonist.

### Claim 36

A method of treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a CpG oligonucleotide and a therapeutically effective amount of a stimulator of interferon genes (STING) agonist.

### Claim 37 (depends on 36)

The method of claim 36, wherein the disease or condition is cancer.

### Claim 38 (depends on 37)

The method of claim 37, wherein the cancer is selected from the group consisting of lymphoma and melanoma.

### Claim 39 (depends on 36)

The method of claim 36, wherein the administering induces interferon γ (IFN-γ) production in the subject.

### Claim 40 (depends on 36)

The method of claim 36, wherein the administering reduces or eliminates a type II immune response and expresses or enhances a type I immune response in the subject.

### Claim 41 (depends on 36)

The method of claim 36, wherein the disease or condition is an allergic disease, and the administering reduces or eliminates IgE-inducing action of the STING agonist.

### Claim 42 (depends on 36)

The method of claim 36, wherein the CpG oligonucleotide is selected from the group consisting of K3 CpG (SEQ ID NO: 1), CpG 1826 (SEQ ID NO: 2), and D35 CpG (SEQ ID NO: 3), and the STING agonist is selected from the group consisting of cGAMP, 3′3′-cGAMP, c-di-GMP, c-di-AMP, 2′3′-cGAMP, and DMXAA.

### Claim 43

A method of at least one of: (i) exerting a type I adjuvant effect of a STING agonist in a subject; (ii) enhancing action of a type I adjuvant of a CpG oligonucleotide in a subject; or (iii) reducing or eliminating a type II immune response and expressing or enhancing a type I immune response in a subject, the method comprising administering to the subject a CpG oligonucleotide and a STING agonist.

### Claim 44 (depends on 43)

The method of claim 43, wherein the CpG oligonucleotide and the STING agonist are co-administered as components of a vaccine adjuvant.

### Claim 45 (depends on 44)

The method of claim 44, wherein the vaccine adjuvant is administered via an intranasal or mucosal route.

### Claim 46 (depends on 43)

The method of claim 43, wherein the CpG oligonucleotide is a type K/B CpG oligonucleotide.

### Claim 47 (depends on 43)

The method of claim 43, wherein the STING agonist is selected from the group consisting of cGAMP, 3′3′-cGAMP, c-di-GMP, c-di-AMP, 2′3′-cGAMP, and DMXAA.
